In the long-standing global fight against Human Immunodeficiency Virus (HIV) infection, Highly Active Antiretroviral Therapy (HAART) has been the cornerstone for maintaining patients’ lives and health. As a vital protease inhibitor (PI), Lopinavir—when used in combination with Ritonavir (serving as its pharmacokinetic booster)—has become a core component of second-line and selected first-line treatment regimens. As a professional API supplier, we provide high-purity Lopinavir Powder that meets strict international pharmacopoeia standards, offering reliable Lopinavir API as a pharmaceutical-grade raw material guarantee for global pharmaceutical companies to produce anti-AIDS formulations.
Lopinavir: A Cornerstone HIV Protease Inhibitor
Lopinavir belongs to the class of HIV-1 and HIV-2 protease inhibitors. Its mechanism of action involves the selective inhibition of virus-encoded protease, preventing the cleavage of viral gag-pol polyprotein precursors, thereby resulting in the production of immature and non-infectious viral particles. As a potent anti-infective agent, it is specifically used for treating HIV infection and serves as a critical component in therapeutic regimens. Clinically, it is almost always co-administered with low-dose Ritonavir (Lopinavir booster), which significantly enhances its plasma concentration and therapeutic efficacy by inhibiting hepatic metabolism of Lopinavir, forming the classic combination formulation.
Core Raw Material Form: High-Purity API Powder
Our flagship product is high-purity Lopinavir Powder. As a key raw material, its quality directly impacts the bioavailability, efficacy, and safety of final oral formulations (primarily tablets or oral solutions). Through advanced synthesis and purification processes, we ensure our product meets rigorous standards of major pharmacopoeias including USP and EP in critical quality attributes such as chemical purity, related substances, crystal form, and residual solvents, fulfilling the strict requirements for pharmaceutical-grade Lopinavir and providing a solid foundation for downstream combination drug production.
Defined Application Areas: Oral Anti-HIV Combination Formulations
The application of Lopinavir API is highly concentrated in the production of oral anti-HIV combination formulations:
- Combination Oral Tablets: High-purity Lopinavir API serves as the core active ingredient in manufacturing “Lopinavir/Ritonavir” fixed-dose combination tablets, which significantly improve patient medication adherenceFDA Access Data.
- Oral Solutions/Suspensions: Particularly designed for treating pediatric HIV-infected patients. Lopinavir Powder is the starting material for preparing such liquid formulationsFDA Access Data.
All applications aim to provide potent and sustained viral suppression, representing an essential part of comprehensive anti-AIDS treatment strategies. It is important to note that it must be used in combination with Ritonavir and is not recommended for monotherapy.
Quality and Global Public Health Commitment
We deeply recognize that APIs used for treating major public health diseases like HIV/AIDS carry value beyond commercial interests in terms of quality and supply chain reliability. Our production system fully complies with cGMP, and we are committed to ensuring stable and compliant supply of Lopinavir API. What we provide is not only high-quality raw material but also part of our commitment to supporting global access to high-quality antiretroviral drugs, especially in low- and middle-income countries.
Conclusion
In the ongoing global campaign against HIV/AIDS, reliable supply of high-quality Lopinavir API is crucial. Our Lopinavir API Powder, leveraging its proven core position in HAART regimens, unique boosting mechanism when combined with Ritonavir, exceptional pharmaceutical-grade quality, and unwavering supply chain responsibility, is dedicated to becoming your trusted strategic partner in producing life-saving anti-HIV medications.
